Cargando…
Effects of BD1047, a σ(1) receptor antagonist, on the expression of mTOR, Camk2γ and GSK-3β in fluvoxamine-treated N2a cells
Fluvoxamine, a common antidepressant agent, is designed to exert its pharmacological effect by inhibiting synaptic serotonin reuptake. However, increasing evidence has demonstrated that σ(1) receptors are likely to be involved in the mechanism of action of fluvoxamine. The present study aimed to obs...
Autores principales: | SU, DONG-AN, JIANG, RI-YUE, LIU, NING, DING, LIANG-CAI, WANG, DA-MING, YU, HAI-YING, YAN, EN-SHI, ZHU, MEI-HUA, ZHU, BIN |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881039/ https://www.ncbi.nlm.nih.gov/pubmed/24396420 http://dx.doi.org/10.3892/etm.2013.1438 |
Ejemplares similares
-
The Peripheral Role of CCL2 in the Anti-Nociceptive Effect of Sigma-1 Receptor Antagonist BD1047 on Inflammatory Hyperalgesia in Rats
por: Chun, Sungkun, et al.
Publicado: (2021) -
Sigma-1 Receptor Antagonist (BD1047) Decreases Cathepsin B Secretion in HIV-Infected Macrophages Exposed to Cocaine
por: López, Omar Vélez, et al.
Publicado: (2018) -
Sigma-1 Receptor Antagonist BD1047 Reduces Mechanical Allodynia in a Rat Model of Bone Cancer Pain through the Inhibition of Spinal NR1 Phosphorylation and Microglia Activation
por: Zhu, Shanshan, et al.
Publicado: (2015) -
CaMK4 overexpression in polycystic kidney disease promotes mTOR-mediated cell proliferation
por: Zhang, Yan, et al.
Publicado: (2022) -
CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway
por: Jin, Qianxu, et al.
Publicado: (2022)